$0.67
-2.29%
N/A-$0.02
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead ...
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead ...
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | WIGGANS THOMAS G | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | Lucas Svetlana | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | Crutcher Patrick J | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | EMSTER KURT VON | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
| Jul 31, 2026 | Shizuru Judith Anne | director | Stock Option (Right to Buy | A | 7,500 | $0.63 |
매수/매도 주식 수와 종가 추세(공통 일간 가격 소스)
X축: 주식 수, 총 주식 수 내림차순
X축: 건수, A+D 건수 내림차순
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 | 금액 |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | WIGGANS THOMAS G | director | Stock Option (Right to Buy | A | 7,500 | $0.63 | $4,725.00 |
| Jul 31, 2026 | Lucas Svetlana | director | Stock Option (Right to Buy | A | 7,500 | $0.63 | $4,725.00 |
| Jul 31, 2026 | Crutcher Patrick J | director | Stock Option (Right to Buy | A | 7,500 | $0.63 | $4,725.00 |
| Jul 31, 2026 | EMSTER KURT VON | director | Stock Option (Right to Buy | A | 7,500 | $0.63 | $4,725.00 |
| Jul 31, 2026 | Shizuru Judith Anne | director | Stock Option (Right to Buy | A | 7,500 | $0.63 | $4,725.00 |
| Jul 20, 2026 | Ros Matthew E | officer: Chief Operating Officer | Non-Voting Convertible Preferred Stock | A | 881 | — | — |
| Jul 20, 2026 | Crutcher Patrick J | director | Non-Voting Convertible Preferred Stock | A | 888 | — | — |
| Jul 16, 2026 | Keenan Greg | officer: Chief Medical Officer | Stock Option (Right to Buy) | — | 103,204 | $0.01 | $1,032.04 |
| Jul 16, 2026 | Keenan Greg | officer: Chief Medical Officer | Stock Option (Right to Buy) | — | 92,278 | $0.61 | $56,289.58 |
| Jul 16, 2026 | Song Wenru | officer: EVP, Head of R&D | Voting Common Stock | — | 0 | — | — |